Skip to main content

Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study



New direct-acting antiviral therapies have revolutionized hepatitis C virus (HCV) infection therapy. Nonetheless, once liver cirrhosis is established, the risk of hepatocellular carcinoma (HCC) still exists despite virus eradication. Late HCV diagnosis hinders timely access to HCV treatment. Thus, we determined trends and risk factors associated with late HCV among patients with a diagnosis of HCC in Taiwan.


We conducted a population-based unmatched case–control study. 2008–2018 Claims data were derived from the Taiwan National Health Insurance Research Database. Individuals with an initial occurrence of liver cancer between 2012 and 2018 were included. The late HCV group were referred as individuals who were diagnosed with HCC within 3 years after HCV diagnosis. The control group were referred as individuals who were diagnosed more than 3 years after the index date. We used multivariable logistic models to explore individual- and provider-level risk factors associated with a late HCV diagnosis.


A decreasing trend was observed in the prevalence of late HCV-related HCC diagnosis between 2012 and 2018 in Taiwan. On an individual level, male, elderly patients, patients with diabetes mellitus (DM), and patients with alcohol-related disease had significantly higher risks of late HCV-related HCC diagnosis. On a provider level, patients who were mainly cared for by male physicians, internists and family medicine physicians had a significantly lower risk of late diagnosis.


Elderly and patients who have DM and alcohol related disease should receive early HCV screening. In addition to comorbidities, physician factors also matter. HCV screening strategies shall take these higher risk patients and physician factors into consideration to avoid missing opportunities for early intervention.

Peer Review reports


Hepatitis C virus (HCV) is a major cause of liver cancer and morbidity and mortality worldwide [1]. In 2005, 123 million people contracted HCV [1]; by 2015, this number increased to more than 185 million [2, 3]. HCV prevalence also increased from approximately 2% in 2005 to up to 4.4% in 2015 in Taiwan [4, 5]. The direct health care costs of HCV-related disease are enormous, and costs are especially high for patients with end stage liver disease [6].

Currently, new HCV treatments are becoming more readily available. New direct-acting antiviral (DAA) therapies are one example of revolutionized therapies for HCV infection. DAA therapies cause fewer adverse effects and allow higher degrees of viral clearance than traditional therapies [7, 8]. Without the development of an effective prophylactic vaccine [9], DAA therapy provides virus prevention by reducing the risk of HCV transmission [10, 11]. Nonetheless, once liver cirrhosis is established, the risk of hepatocellular carcinoma (HCC) still exists despite virus eradication with DAA therapy [12, 13]. Therefore, in addition to researching the epigenetic mechanisms involved in HCV-related HCC [14], it is equally critical to prevent late diagnosis of HCV. Early detection of HCV may improve access to timely HCV treatment and help health care providers overcome the HCC treatment hurdle.

Although HCC surveillance significantly improves early tumor detection, curative therapies, and improvement of survival [15], poor adherence to HCC surveillance guidelines in high-risk patients may lead to lower proportions of HCC diagnosis via screening among retrospective studies, which were closer to real-world clinical practice [16]. Because patients do not often experience early symptoms of HCV, less than 50% of patients notice their HCV infections [17]. Thus, viral infection is initially difficult to diagnose, and it is challenging to estimate its incidence [1]. The progression of the disease varies from person to person and begins with no symptoms during the early stage of infection [18]. HCV infection usually takes 30 or more years to develop into end stage liver disease (ESLD) [18]. Moorman et al. found that 17% of individuals were diagnosed as having HCV and cirrhosis simultaneously; this indicates a late diagnosis of HCV, which obstructs the ability for patients to obtain early interventions and therapies [19]. The difficulty in diagnosing HCV due to lack of symptoms, along with unidentified risk factors of the disease, is likely to lead to late diagnosis of HCV infection and related HCC.

According to previous research, several additional factors may be associated with late HCV-related HCC diagnosis and hinder timely access to appropriate treatments. Illegal drug use [20, 21], older age upon infection [18], less likelihood to exhibit medical care–seeking behavior [22], low income or socioeconomic status (SES) [19], and distance from a health care provider [23] have also been identified as risk factors for late HCV diagnosis. Critically, the literature illustrates that excessive alcohol intake and coinfection with human immunodeficiency virus (HIV) [24] may accelerate the progression of HCV, cause earlier development of cirrhosis or HCC, and increase the risk of late HCC diagnosis, reducing the opportunity for patients to receive timely treatment [18].

Studies have focused on known risk factors such as illegal drug use, alcohol use, SES, physician visits, and residential area [19, 22, 23, 25]. Despite increased knowledge of these risk factors, the rate of late diagnosis is still not optimal. The increasing prevalence of chronic conditions, along with patient and provider behaviors, may be hidden factors contributing to under-diagnosis and late diagnosis of HCV. To identify more hidden and unexplored risk factors for late diagnosis, our research analyzed patient characteristics, such as multiple chronic conditions and routine medical checkups, as well as factors related to the health care environment, such as health care provider characteristics [26, 27]. We examined the trend of late HCV-related HCC diagnosis rates over time and explored individual- and provider-related factors associated with late HCV diagnosis among patients with newly diagnosed HCC under the National Health Insurance program in Taiwan, a typical single-payer universal health insurance plan.


Study design and data source

The main data source of this population-based unmatched case control study was the 2008–2018 National Health Insurance Research Database (NHIRD). The NHIRD contains health care data of 99% of the population of Taiwan and includes comprehensive claims and enrollment information, including demographic data, dates of clinical visits and admission, diagnostic codes, and prescription details. NHIRD used the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) to record diagnoses prior to January 2016 and used the 10th Revision (ICD-10-CM) thereafter.

Study population

We used the NHI claims files to identify individuals with an initial occurrence of liver cancer (ICD-9-CM codes 155.0, 155.2/ICD-10-CM codes C22.0, C22.2, C22.3, C22.4, C22.7, C22.8, C22.9, Z51.12) from January 1, 2012, to December 31, 2018. The eligible participants were divided into two groups based on the amount of time between HCV diagnosis (ICD-9-CM codes V02.62, 070.41, 070.44, 070.51, and 070.54/ ICD-10-CM codes B17.11, B19.21, B18.2, B17.10, B19.20, B18.2, Z22.52) and occurrence of HCC. The late group was defined as having a time lag of 3 years or fewer between HCV diagnosis and HCC diagnosis, including the HCC diagnosis elicited testing and subsequent HCV diagnosis. This indicated delayed diagnosis of HCV infection due to the slow progression nature of HCV [18]. The control group was defined as if individuals were diagnosed with HCV more than 3 years before their HCC diagnosis. Sensitivity analyses were conducted using two alternative time cut-offs (2 years and 5 years) in the definitions of late diagnosis of HCV. We identified 14,337 patients with HCC who had been previously diagnosed with HCV. The exclusion criteria included hepatitis B virus (HBV) infection, end stage renal disease (ESRD), and chronic hepatitis in other disease. After these patients were excluded, we identified 6703 documented clinical diagnoses of HCV-related HCC, 3733 of which were in the late group and 2970 of which were in the control group (Fig. 1).

Fig. 1
figure 1

Flow chart for selection of late HCV group and control group. HCV = hepatitis C virus; HCC = hepatocellular carcinoma; HBV = hepatitis B virus; ESRD = end stage of renal disease

Patient characteristics

The demographic data collected were patient age, sex, and comorbidities. Comorbidities were defined as diseases that existed within 3 years before the date of HCV diagnosis. The comorbidities identified in this study were diabetes mellitus (DM), dyslipidemia, psychiatric disorders, alcohol-related disease, and malignancy disease. DM, dyslipidemia, psychiatric disorders including schizophrenia, depression, and anxiety were identified using one inpatient discharge record or at least two outpatient visits with the specific diagnosis and disease-related prescriptions. Alcohol-related diseases were identified using one inpatient discharge record or at least two outpatient visits with the specific diagnosis. Patients with malignancy and hematological malignancy excluding HCC were identified using the NHI catastrophic illness file records. The related ICD-9/10-CM codes were provided in Appendix A (Additional file 1). Health care–seeking behavior included the variables of outpatient utilization and medical checkups. Outpatient utilization was defined as the number of outpatient visits within 3 years preceding the date of HCV diagnosis and was categorized into four levels: very low, low, medium, and high. The routine checkup variable was defined as whether individuals had undergone any routine medical checkup within 3 years preceding the HCV diagnosis. The NHI monthly wage and enrollment category was used as a proxy for SES. People without a well-defined monthly payroll were categorized into two groups: union or association members such as members of farmers’ associations and members of a lower income group such as veterans [28]. We divided SES into four categories: a well-defined monthly payroll of more than NT$60,000, a monthly income of less than NT$60,000, union or association members, and a lower income group (NT: New Taiwan dollars; US$1 = approximately NT$30.24).

Provider characteristics

Taiwanese people enjoy complete freedom in choosing their care providers under the NHI program [29, 30]. Thus, health care providers were defined as providers who provided most of the medical services to an individual within 3 years before the HCV diagnosis in our analysis. The provider-level characteristics identified in this study were physician age, sex, and specialty. Under the NHI program in Taiwan, hospitals are classified according to their accreditation status, quality, staffing, and infrastructure. Accreditation status was divided into three categories: medical center, regional hospitals, and district hospitals and clinics. Hospital ownership was defined as public or private.

Statistical analysis

Chi-squared and Student’s t tests were used to examine the differences between the late HCV group and control group. An unconditional logistic regression model was used to estimate the relative magnitudes of these differences. Odds ratio (OR) and 95% confidence intervals (CI) were calculated with the control group as the reference group. We identified trends in late HCV-related HCC diagnosis from 2012 to 2014 to 2017 to 2018. Next, we used multivariate logistic models to explore the predictors at both the individual and provider levels. All statistical analyses were performed using the SAS System for Windows Version 9.4 software (SAS Institute, Cary, NC, USA).


Characteristics of the late HCV-related HCC group and control group

Of all 6703 HCC patients who received the diagnosis during the study period, the proportion of late HCV-related HCC diagnoses decreased over time, from 70.30% between 2012 and 2014 to 41.41% between 2017 and 2018 (Fig. 2). Patients in the late group were significantly in male patients and patients older than those in the control group. In addition, compared with the control group, a higher proportion of patients in the late group had DM, alcohol-related disease, no routine medical checkups. A higher proportion of patients with late group were cared by, providers who were 55 years or older, female physician, and other specialties. Moreover, a lower proportion of patients with late group were union or association members, compared with the control group (Table 1).

Fig. 2
figure 2

Trend in late diagnosis of hepatitis C virus related hepatocellular carcinoma between 2012–2014 and 2017–2018

Table 1 Demographic characteristics of patients with hepatitis C virus who were diagnosed late relative to hepatocellular carcinoma in Taiwan

Factors and odds associated with late HCV-related HCC diagnosis

In the univariate analyses, the following factors were associated with significantly higher odds of late diagnosis: male patients (OR, 1.37; 95% CI, 1.24–1.51), patients aged 67 years or above (OR, 1.04; 95% CI, 1.04–1.05), with DM (OR, 1.16; 95% CI, 1.03–1.30), and alcohol-related disease (OR, 2.24; 95% CI, 1.64–3.07) (Table 2). By contrast, patients who had undergone a routine medical checkup were less likely to have a late HCV-related HCC diagnosis (OR, 0.62; 95% CI, 0.56–0.69). A dose response was observed between physician’s age and late HCV diagnosis. Patients who were treated by physicians aged 55 years or older had the highest odds of having a late HCV-related HCC diagnosis, followed by those cared by physicians aged 45–54 years (OR, 0.61; 95% CI, 0.54–0.68), and the last by physicians aged below 45 years (OR, 0.57; 95% CI, 0.50–0.65). Compared with patients who were mainly cared for by female physicians, patients who were mainly cared for by male physicians had a significantly lower risk of late HCV diagnosis (OR, 0.78; 95% CI, 0.63–0.95).

Table 2 Multiple logistic regression analysis of the predictive factors associated with late HCV among patients with a diagnosis of HCC

Compared with patients who received medical care primarily from internists, patients mainly cared for by other specialties had a significantly higher risk of having a late HCV diagnosis (OR, 1.31; 95% CI, 1.17–1.47) (Table 2).

After adjustment, the following factors were associated with significantly higher odds of late diagnosis: male patients (adjusted OR [AOR], 1.59; 95% CI, 1.43–1.77), patients aged 67 years or above (AOR, 1.06; 95% CI, 1.05–1.06), with DM (AOR, 1.18; 95% CI, 1.04–1.34), and alcohol-related disease (AOR, 2.95; 95% CI, 2.11–4.13) (Table 2). By contrast, patients who had more outpatient service utilization were significantly less likely to have a late HCV diagnosis. Compared to very lower group of outpatient service utilization, lower group (AOR, 0.85; 95% CI, 0.73–0.98), middle group (AOR, 0.82; 95% CI, 0.70–0.95), and higher group (AOR, 0.73; 95% CI, 0.62–0.85) were less likely to have a late HCV diagnosis. Patients who had undergone a routine medical checkup were less likely to have a late HCV diagnosis (AOR, 0.58; 95% CI, 0.52–0.65). Interestingly, significant variations were observed among providers. A dose response was observed between physician’s age and late HCV diagnosis. Compared to patients who were treated by physicians aged 55 years or older, less likely to have a late HCV diagnosis by those cared by physicians aged 45–54 years (AOR, 0.62; 95% CI, 0.55–0.70) and followed by those cared by physicians aged below 45 years (AOR, 0.53; 95% CI, 0.47–0.61). Compared with patients who were mainly cared for by female physicians, patients who were mainly cared for by male physicians had a significantly lower risk of late HCV diagnosis (AOR, 0.70; 95% CI, 0.56–0.87). Compared with patients who received medical care primarily from internists, patients mainly cared for by other specialties had a significantly higher risk of having a late HCV diagnosis (AOR, 1.28; 95% CI, 1.13–1.45) (Table 2).


Under the single-payer comprehensive universal health insurance program in Taiwan, the proportion of late HCV diagnoses has been decreasing over time. However, approximately 41% of patients still received a late HCV-related HCC diagnosis between 2017 and 2018. Continuing efforts are warranted to avoid missing the opportunity of earlier HCV diagnosis and developing serious liver disease.

In addition to factors repeatedly discussed in the literature (age, alcohol related disease, illicit drug use problems, health care–seeking behaviors, and SES), we identified additional patient and provider characteristics that were significantly associated with a higher risk of late HCV diagnosis. The first major risk factor was diabetes. Our findings illustrated that DM patients had a significantly higher risk of late HCV-related HCC diagnosis, regardless of sex and age. One would expect that DM patients tend to have more medical interactions and hence, their HCV are more likely to be detected earlier. One plausible explanation is that DM has the potential to accelerate processes associated with liver carcinogenesis, shortening the timeline in which HCV infection can lead to development of HCC [31, 32]. Regarding DM and the risk of HCV-related HCC, the relative risk (RR) of cohort studies have been shown to be 3.25 [33], and 3.1 [34] in Taiwan and 2.0 [35] and 1.73 [32] in Japan. This may be because DM is a crucial risk factor for nonalcoholic fatty liver disease [36] and nonalcoholic steatohepatitis [37], which increases the risk of HCC. Thus, DM patients require more active monitoring for HCC development [38], especially in the cirrhosis state [39]. Furthermore, DM may lead to more severe liver inflammation and fibrosis progression [40]. DM might be mediated by binding of insulin-like growth factor-1 (IGF-1) to the IGF-1 receptor and activate mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathways leading to increased cell proliferation and decreased apoptosis [41]. Insulin resistance (IR), which has a negative impact on antiviral therapy responses [42] and liver-related outcomes [43], plays a crucial role in fibrosis progression. HCV infection promotes IR through the insulin signaling pathway in hepatocytes and lead to a rise in levels of tumor necrosis factor and interleukin-6 [44], which aid the advancement of liver steatosis and inflammation and subsequent cancer. Similar to the previous research [45], HCV-related fibrosis development was obviously accelerated in older patients and HCC were higher in older HCV patients, compared with younger patients. Thus, elderly DM patients should be considered the high-risk group for late HCV-related HCC.

HCC is more prevalent in men, which is associated with androgen receptor (AR) as a central role of sex preference [46, 47]. AR belongs to the superfamily of nuclear receptor [48, 48] and nuclear AR overexpression is allied with the progression of HCC [47]. To be specific, mammalian target of rapamycin (mTOR) signaling contributes a plausible molecular mechanism by virtue of enhanced AR protein stability through antagonizing proteasomal degradation and increasing nuclear localization [47]. Inhibition of AR induces AKT-mTOR signaling. Thus, targeting both AR and mTOR might be a promising therapeutic strategy for HCC, especially mTOR complex 1 (mTORC1), which facilitates AR nuclear localization and transactivation independently and together with androgen [46, 47]. HCV core protein also enhances AR-mediated signaling, which in turn upregulates vascular endothelial growth factor (VEGF) expression in hepatocytes and facilitates angiogenesis [49]. Immune system activation through the senescence-associated secretory phenotype (SASP), abnormal senescent cell accumulation, and pre-malignant hepatocytes evading senescence arrest lead to HCC occurrence [50]. HCV core protein bypasses normal stress-induced senescence by downregulating p16 [51]; furthermore, elevated T cell senescence and oxidative stress induced by HCV contribute to proliferation of pre-malignant cells [50]. Thus, a combination of pro-senescence therapy to stop tumor growth, with anti-senescence therapy to clear the senescent cells might be a convincing senescence-modulating treatment [52].

Another important risk factor is patients’ health care–seeking behaviors. Consistent with previous literature, we found that patients who had undergone a routine medical checkup or had more outpatient utilization were significantly less likely to have a late HCV diagnosis. In our study and the study by Samji et al. [22], a time period shorter than 2 or 3 years between the HCV diagnosis and occurrence of HCC was considered late diagnosis, both found that patients with a late HCV diagnosis had lower outpatient service utilization. Because HCC is likely to progress with no obvious initial symptoms, persons who were more attentive to their health or had more interactions with health care providers may have an increased likelihood of earlier diagnosis.

More importantly, our study found that provider characteristics play a crucial role in rates of late diagnosis. After adjusting for physician specialty and other variables, patients who were mainly cared for by female physicians had a significantly higher risk of late diagnosis. One plausible explanation may be the influence of patient-physician gender concordance on screening behaviors. For example, people who were care by male physician would yield a higher prostate cancer screening rate [53]. Female physicians were more likely to recommend human papillomavirus (HPV) vaccine [54] and mammography screening [55]. In our study, there were significantly more male than female HCV-related HCC patients (60.27% vs. 39.73%). Screening strategies shall take physician–patient gender concordance and more effective physician communication into consideration.

In addition, patients who were mainly cared for by older physicians or physicians with non-internal or family medicine specialties had a significantly higher risk of late diagnosis. Heterogeneity in education and training background of physicians, consensus of clinical practice guidelines and screening recommendation, awareness of HCV infection across different age cohorts, and specialty of physicians may have contributed to the variation in their practices.

Our study has several limitations. First, unlike performing liver biopsies to indicate cirrhosis or using mean fibrosis 4 (FIB 4) score for late HCV diagnosis [19], using a 3-year interval as the cutoff for late diagnosis may seem arbitrary. The previous research showed that the DAA group had a significantly higher survival rate than the non-DAA group during 3 years follow up [56]. Another research disclosed the potentially lower risk of severe liver disease among patients with SVR after anti-viral therapy duration of 3-years post-treatment time [57]. In addition, more than half of patients developing HCC within 3 years between HCV diagnosis and HCC diagnosis in our data; therefore, a 3-year interval was used as the cut-off time period for defining ‘‘late” diagnosis. Moreover, because in a typical disease course it takes approximately 20 to 30 years or longer for HCV infection to develop into HCC, our result may be biased toward the null. The true magnitude of late diagnosis may be much higher than that observed. We also performed the sensitivity analysis using 2-year and 5-year time lag (data not shown) as the cut-offs and the main results remained robust. Second, the use of ICD-9/10-CM codes may yield potential misclassification bias. Therefore, to reduce potential misclassification bias, we used the HCC recorded in the registry of the Catastrophic Illness Patient Database as our end point, not liver cirrhosis. This is because the NHI program requires a histologic confirmation and undertakes a review process for officially recording a diagnosis of liver cancer in in the registry of the Catastrophic Illness Patient Database. Third, patients with drug abuse and HIV have not been analyzed due to a small sample size. Fourth, due to the inherited limitations of claims data, some important confounding factors such as education and clinical symptoms may not be perfectly controlled in the analyses. Residual confounding bias may be possible.

This population-based study with a large number of HCC cases allows us to provide robust estimates of risk factors associating with delayed diagnosis of HCV infection. However, continued efforts in narrowing the gaps for effective secondary prevention and treatment are needed [58]. Taiwan has implemented a policy to improve treatment access to reduce DAA cost to approximately US$750 for a 12-week therapy course. Taiwan HCV screening policy is that people more than 45 years-old and aboriginals more than 40 years-old had the once in a lifetime to receive HCV screening. Early diagnosis and identification of patients is critical for effective decision-making for HCV treatment. Robust governmental action, such as in the case of Taiwan, is warranted to eliminate HCV before 2030 [58]. Similar to the policies such as time testing for individuals born between 1945 and 65 [59, 60] and risk-based screening for illegal drug users [61], routine HCV screening in high-risk groups such as DM and alcohol related disease may help reduce the late HCV diagnosis. Timely diagnosis and treatment for HCV related HCC was suboptimal at the population level. The shorter the length of time between HCV and HCC diagnoses might represent poor HCV management. If DM patients were to diagnose HCV early enough, more timely diagnosis of cirrhosis and early screening and treatment intervention care then proceed, and reduce the risk of the patient developing HCC in the first place. Hospital-based HCV screening [62, 63] for elderly DM patients should be considered as a model for early diagnosis.


We recommend that elderly and patients who have DM and alcohol related disease receive early HCV screening and reduce the incidence of inoperable HCC. The finding also highlights the role of health care providers in improving early detection of HCV [27].

Availability of data and materials

Data are available from the Collaboration Center of Health Information Application of the Ministry of Health and Welfare. The data utilized in this study cannot be made available in the paper, the supplemental files, or in a public repository due to the ‘‘Personal Information Protection Act’’ executed by Taiwan’s government, starting from 2012. Requests for data can be sent directly to the Collaboration Center of Health Information Application of the Ministry of Health and Welfare (



Hepatitis C virus


Direct-acting antiviral


Hepatocellular carcinoma


End stage liver disease


Socioeconomic status


Human immunodeficiency virus


National Health Insurance Research Database

ICD-9/10- CM:

International Classification of Diseases, 9th/10th Revision, Clinical Modification


Hepatitis B virus


End stage renal disease


Diabetes mellitus


New Taiwan dollars


Odds ratio

95% CI:

95% Confidence intervals


Adjusted odds ratio


Relative risk


Insulin-like growth factor-1


Mitogen-activated protein kinase


Phosphoinositide 3-kinase


Protein kinase B


Insulin resistance


Androgen receptor


Mammalian target of rapamycin


MTOR complex 1


Vascular endothelial growth factor


Senescence-associated secretory phenotype


Human papillomavirus

FIB 4:

Fibrosis 4


  1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5(9):558–67.

    Article  Google Scholar 

  2. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.

    Article  Google Scholar 

  3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333–42.

    Article  Google Scholar 

  4. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(Suppl 2):61–80.

    Article  Google Scholar 

  5. Bennett H, Waser N, Johnston K, Kao JH, Lim YS, Duan ZP, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int. 2015;9(3):378–90.

    Article  Google Scholar 

  6. Gordon SC, Pockros PJ, Terrault NA, Hoop RS, Buikema A, Nerenz D, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012;56(5):1651–60.

    Article  Google Scholar 

  7. Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–28.

    Article  CAS  Google Scholar 

  8. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373(27):2599–607.

    Article  CAS  Google Scholar 

  9. Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol. 2014;61(1 Suppl):S34-44.

    Article  Google Scholar 

  10. Chen DS, Locarnini S, Wait S, Bae SH, Chen PJ, Fung JY, et al. Report from a viral hepatitis policy forum on implementing the WHO framework for global action on viral hepatitis in North Asia. J Hepatol. 2013;59(5):1073–80.

    Article  Google Scholar 

  11. Heffernan A, Cooke GS, Nayagam S, Thursz M, Hallett TB. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model. Lancet. 2019;393(10178):1319–29.

    Article  Google Scholar 

  12. Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157(5):1264–78.

    Article  CAS  Google Scholar 

  13. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–33.

    Article  CAS  Google Scholar 

  14. Perez S, Kaspi A, Domovitz T, Davidovich A, Lavi-Itzkovitz A, Meirson T, et al. Hepatitis C virus leaves an epigenetic signature post cure of infection by direct-acting antivirals. PLoS Genet. 2019;15(6): e1008181.

    Article  CAS  Google Scholar 

  15. Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, et al. HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis. J Hepatol. 2022;77(1):128–39.

    Article  Google Scholar 

  16. Zhao C, Jin M, Le RH, Le MH, Chen VL, Jin M, et al. Poor adherence to hepatocellular carcinoma surveillance: a systematic review and meta-analysis of a complex issue. Liver Int. 2018;38(3):503–14.

    Article  Google Scholar 

  17. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859–61.

    Article  CAS  Google Scholar 

  18. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41–52.

    Article  CAS  Google Scholar 

  19. Moorman AC, Xing J, Ko S, Rupp LB, Xu F, Gordon SC, et al. Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): missed opportunities for intervention. Hepatology. 2015;61(5):1479–84.

    Article  Google Scholar 

  20. Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): a systematic review and meta-analysis. Int J Drug Policy. 2015;26(10):911–21.

    Article  Google Scholar 

  21. Yang J, Zhang Y, Luo L, Meng R, Yu C. Global mortality burden of cirrhosis and liver cancer attributable to injection drug use, 1990–2016: an age-period-cohort and spatial autocorrelation analysis. Int J Environ Res Public Health. 2018;15(1).

  22. Samji H, Yu A, Kuo M, Alavi M, Woods R, Alvarez M, et al. Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development. J Hepatol. 2017;67(5):909–17.

    Article  Google Scholar 

  23. Monnet E, Ramée C, Minello A, Jooste V, Carel D, Di Martino V. Socioeconomic context, distance to primary care and detection of hepatitis C: a French population-based study. Soc Sci Med. 2008;66(5):1046–56.

    Article  Google Scholar 

  24. Fleisher I, Geboy AG, Nichols W, Desale S, Fernandez S, Basch P, et al. HIV testing in patients who are HCV positive: compliance with CDC guidelines in a large healthcare system. PLoS ONE. 2021;16(6): e0252412.

    Article  CAS  Google Scholar 

  25. Alavi M, Law MG, Grebely J, Amin J, Hajarizadeh B, George J, et al. Time to decompensated cirrhosis and hepatocellular carcinoma after an HBV or HCV notification: a population-based study. J Hepatol. 2016;65(5):879–87.

    Article  Google Scholar 

  26. Goldberg DS, Valderrama A, Kamalakar R, Sansgiry SS, Babajanyan S, Lewis JD. Hepatocellular carcinoma surveillance among cirrhotic patients with commercial health insurance. J Clin Gastroenterol. 2016;50(3):258–65.

    Article  CAS  Google Scholar 

  27. Tsay CJ, Lim JK. Assessing the effectiveness of strategies in US Birth Cohort screening for hepatitis C infection. J Clin Transl Hepatol. 2020;8(1):25–41.

    Google Scholar 

  28. Liu TL, Tsay JH, Chou YJ, Huang N. Comparison of the perforation rate for acute appendicitis between nationals and migrants in Taiwan, 1996–2001. Public Health. 2010;124(10):565–72.

    Article  Google Scholar 

  29. Liang LL, Huang N, Shen YJ, Chen AY, Chou YJ. Do patients bypass primary care for common health problems under a free-access system? Experience of Taiwan. BMC Health Serv Res. 2020;20(1):1050.

    Article  Google Scholar 

  30. Cheng TM. Reflections on the 20th anniversary of Taiwan’s single-payer National Health Insurance System. Health Aff (Millwood). 2015;34(3):502–10.

    Article  Google Scholar 

  31. Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y, et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2012;130(7):1639–48.

    Article  CAS  Google Scholar 

  32. Arase Y, Kobayashi M, Suzuki F, Suzuki Y, Kawamura Y, Akuta N, et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology. 2013;57(3):964–73.

    Article  CAS  Google Scholar 

  33. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135(1):111–21.

    Article  CAS  Google Scholar 

  34. Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2054–60.

    Article  CAS  Google Scholar 

  35. Kawamura Y, Arase Y, Ikeda K, Hirakawa M, Hosaka T, Kobayashi M, et al. Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients. Am J Med. 2010;123(10):951-6.e1.

    Article  CAS  Google Scholar 

  36. Kramer JR, Natarajan Y, Dai J, Yu X, Li L, El-Serag HB, et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology. 2022;75(6):1420–8.

    Article  CAS  Google Scholar 

  37. Liang J, Ariizumi SI, Nakano M, Yamamoto M. Diabetes mellitus and/or nonalcoholic steatohepatitis-related hepatocellular carcinoma showed favorable surgical outcomes after hepatectomy. Anticancer Res. 2019;39(10):5639–43.

    Article  CAS  Google Scholar 

  38. Chen J, Han Y, Xu C, Xiao T, Wang B. Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases: a meta-analysis of cohort studies. Eur J Cancer Prev. 2015;24(2):89–99.

    Article  Google Scholar 

  39. Veldt BJ, Chen W, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology. 2008;47(6):1856–62.

    Article  Google Scholar 

  40. Dyal HK, Aguilar M, Bhuket T, Liu B, Holt EW, Torres S, et al. Concurrent obesity, diabetes, and steatosis increase risk of advanced fibrosis among HCV patients: a systematic review. Dig Dis Sci. 2015;60(9):2813–24.

    Article  CAS  Google Scholar 

  41. Lee EJ, Shin CM, Lee DH, Han K, Park SH, Kim YJ, et al. The Association between cholecystectomy and the risk for fracture: a Nationwide Population-Based Cohort Study in Korea. Front Endocrinol (Lausanne). 2021;12: 657488.

    Article  Google Scholar 

  42. Romero-Gómez M, Del Mar VM, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128(3):636–41.

    Article  Google Scholar 

  43. Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: a contemporary review. World J Gastroenterol. 2017;23(9):1697–711.

    Article  CAS  Google Scholar 

  44. Hung CH, Lee CM, Lu SN. Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther. 2011;9(5):525–33.

    Article  CAS  Google Scholar 

  45. Asahina Y, Tsuchiya K, Tamaki N, Hirayama I, Tanaka T, Sato M, et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52(2):518–27.

    Article  CAS  Google Scholar 

  46. Zhang H, Spencer K, Burley SK, Zheng XFS. Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discov Today. 2021;26(6):1539–46.

    Article  CAS  Google Scholar 

  47. Zhang H, Li XX, Yang Y, Zhang Y, Wang HY, Zheng XFS. Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross-talk in hepatocellular carcinoma. Hepatology. 2018, 2271–86.

  48. Kanda T, Yokosuka O. The androgen receptor as an emerging target in hepatocellular carcinoma. J Hepatocell Carcinoma. 2015;2:91–9.

    Article  Google Scholar 

  49. Kanda T, Steele R, Ray R, Ray RB. Hepatitis C virus core protein augments androgen receptor-mediated signaling. J Virol. 2008;82(22):11066–72.

    Article  CAS  Google Scholar 

  50. Giannakoulis VG, Dubovan P, Papoutsi E, Kataki A, Koskinas J. Senescence in HBV-, HCV- and NAFLD- mediated hepatocellular carcinoma and senotherapeutics: current evidence and future perspective. Cancers. 2021, 13(18).

  51. Lim JS, Park SH, Jang KL. Hepatitis C virus Core protein overcomes stress-induced premature senescence by down-regulating p16 expression via DNA methylation. Cancer Lett. 2012;321(2):154–61.

    Article  CAS  Google Scholar 

  52. Mittermeier C, Konopa A, Muehlich S. Molecular mechanisms to target cellular senescence in hepatocellular carcinoma. Cells. 2020, 9(12).

  53. Shungu N, Diaz VA, Perkins S, Kulshreshtha A. Physician attitudes and self-reported practices toward prostate cancer screening in black and white men. Fam Med. 2022;54(1):30–7.

    Article  Google Scholar 

  54. Hernandez ND, Daley EM, Young L, Kolar SK, Wheldon C, Vamos CA, et al. HPV vaccine recommendations: does a health care provider’s gender and ethnicity matter to Unvaccinated Latina college women? Ethn Health. 2019;24(6):645–61.

    Article  Google Scholar 

  55. Mendoza-Grey S, Ramos-Muniz J, Armbrister AN, Abraído-Lanza AF. Mammography screening among latinas: does gender and ethnic patient-physician concordance matter? J Immigr Minor Health. 2021;23(5):986–92.

    Article  Google Scholar 

  56. Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavò MR, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71(2):265–73.

    Article  CAS  Google Scholar 

  57. Manos MM, Darbinian J, Rubin J, Ray GT, Shvachko V, Denis B, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm. 2013;19(6):438–47.

    Article  Google Scholar 

  58. The Lancet Gastroenterology H. Treatment of hepatitis C: momentum still needed. Lancet Gastroenterol Hepatol. 2018;3(5):289.

  59. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945–1965: recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157(11):817–22.

    Article  Google Scholar 

  60. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012;61(Rr-4):1–32.

  61. Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for Hepatitis C Screening Among Adults—United States, 2020. MMWR Recomm Rep. 2020;69(2):1–17.

    Article  Google Scholar 

  62. Shadaker S, Nasrullah M, Gamkrelidze A, Ray J, Gvinjilia L, Kuchuloria T, et al. Screening and linkage to care for hepatitis C among inpatients in Georgia’s national hospital screening program. Prev Med. 2020;138: 106153.

    Article  Google Scholar 

  63. Park JS, Wong J, Cohen H. Hepatitis C virus screening of high-risk patients in a community hospital emergency department: Retrospective review of patient characteristics and future implications. PLoS ONE. 2021;16(6): e0252976.

    Article  CAS  Google Scholar 

Download references


We would like to thank the Collaboration Center of Health Information Application of the Ministry of Health and Welfare for making the database available for this study. The conclusions presented in this study does not represent the opinions of the Collaboration Center of Health Information Application of the Ministry of Health and Welfare.


There is no financial support.

Author information

Authors and Affiliations



Performing database management, data analysis and statistic testing—H.-Y.H. and Y.-C.C. Study design and implementation of the study—S.-S.C. and N.H. Critical revision—N.H. and Y.-F.Y. Writing—S.-S.C. and N.H. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Nicole Huang.

Ethics declarations

Ethics approval and consent to participate

We confirmed that all methods were performed in accordance to the Declaration of Helsinki. To assure privacy and confidentiality, all data analyses were carried out onsite within the Collaboration Center of Health Information Application of the Ministry of Health and Welfare. We abided all government regulations in data management and analyses. This study was approved by The Institutional Review Board (IRB) of Taipei City Hospital approved this study (IRB No.: TCHIRB-10512125-W), and the need for informed consent was waived.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

. Appendix A. Diagnosis codes. Table A Codes of International Classification of Diseases, 9/10th Revision, Clinical Modification (ICD-9/10-CM).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chang, SS., Hu, HY., Chen, YC. et al. Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case–control study. BMC Gastroenterol 22, 425 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Cirrhosis
  • HCC
  • Late HCV diagnosis
  • Diabetes mellitus
  • Early screening